{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T09:43:53Z","timestamp":1776073433850,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Non-Hodgkin lymphoma (NHL) constitutes 90% of all lymphomas and accounts for 2.8% of new cancer cases and 2.6% of cancer-related deaths in 2020. Hematopoietic stem cell transplantation remains the standard treatment for refractory or relapsed NHL. Due to the shortage of carmustine, this study aimed to compare the outcomes of patients undergoing autologous stem cell transplantation (ASCT) with conditioning regimens that either include or exclude this drug over an 11-year period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included a cohort of 240 patients with NHL who underwent ASCT with an EAM conditioning regimen, both with and without carboplatin. Following informed consent, clinical data from patients who underwent transplantation between March 2006 and May 2017 were collected. Patients were followed to assess overall survival (OS) and disease-free survival (DFS) as primary endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      No significant differences were observed between the survival outcomes of the two groups with differing conditioning regimens (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.27 for OS;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.49 for DFS). The 3-year and 5-year OS rates were 81% and 74.8%, respectively, with a median follow-up of 74 months. The 3-year and 5-year DFS rates were 66.6% and 62.1%, respectively. OS and DFS were significantly higher in patients with B-cell lymphomas compared to those with T-cell lymphoma (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our real-world data indicate that the addition of carboplatin to the EAM conditioning regimen does not significantly affect survival outcomes for patients with NHL undergoing ASCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s44313-026-00131-8","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:24:21Z","timestamp":1775712261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autologous bone marrow transplantation in non-Hodgkin lymphoma patients following different conditioning regimens: an 11-year single-center quasi-experimental study"],"prefix":"10.1007","volume":"61","author":[{"given":"Sahar","family":"Tavakoli Shiraji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7858-1330","authenticated-orcid":false,"given":"Mohammad","family":"Biglari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soroush","family":"Rad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Barkhordar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein Kamranzadeh","family":"Foumani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghasem","family":"Janbabaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seied Asadollah","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Vaezi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ardeshir","family":"Ghavamzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"7","key":"131_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720\u201348.","journal-title":"Leukemia"},{"issue":"9844","key":"131_CR2","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380(9844):848\u201357.","journal-title":"Lancet"},{"issue":"3","key":"131_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"131_CR4","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"131_CR5","doi-asserted-by":"crossref","unstructured":"Al-Naeeb AB, Ajithkumar T, Behan S, Hodson DJ. Non-Hodgkin lymphoma. BMJ. 2018;362:k3204.","DOI":"10.1136\/bmj.k3204"},{"issue":"1","key":"131_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.transci.2013.05.029","volume":"49","author":"S Gangatharan","year":"2013","unstructured":"Gangatharan S, Kuruvilla J. Relapsed and refractory aggressive NHL: time for a change. Transfus Apher Sci. 2013;49(1):72\u20139.","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"131_CR7","first-page":"259","volume":"14","author":"A Prakash","year":"2023","unstructured":"Prakash A, Goodman H. Outcomes of autologous stem cell transplantation for non-Hodgkin lymphoma patients at a tertiary referral centre. Middle East J Cancer. 2023;14(2):259\u201369.","journal-title":"Middle East J Cancer"},{"issue":"12","key":"131_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122912","volume":"14","author":"IN Sheikh","year":"2022","unstructured":"Sheikh IN, Elgehiny A, Ragoonanan D, Mahadeo KM, Nieto Y, Khazal S. Management of aggressive non-Hodgkin lymphomas in the pediatric, adolescent, and young adult population: an adult vs. pediatric perspective. Cancers. 2022;14(12):2912.","journal-title":"Cancers"},{"issue":"6","key":"131_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/CCO.0000000000000403","volume":"29","author":"K Benekou","year":"2017","unstructured":"Benekou K, Montoto S. Role of stem cell transplant in lymphoma in the era of new drugs. Curr Opin Oncol. 2017;29(6):455\u20139.","journal-title":"Curr Opin Oncol"},{"key":"131_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1200\/EDBK_349307","volume":"42","author":"H Ngu","year":"2022","unstructured":"Ngu H, Takiar R, Phillips T, Okosun J, Sehn LH. Revising the treatment pathways in lymphoma: new standards of care\u2014how do we choose? Am Soc Clin Oncol Educ Book. 2022;42:629\u201342.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"11","key":"131_CR11","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1038\/bmt.2015.184","volume":"50","author":"N Epperla","year":"2015","unstructured":"Epperla N, Fenske T, Lazarus H, Hamadani M. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? Bone Marrow Transplant. 2015;50(11):1393\u2013404.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"131_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1182\/asheducation-2015.1.82","volume":"2015","author":"KA Blum","year":"2015","unstructured":"Blum KA. B-cell receptor pathway modulators in NHL. Hematology Am Soc Hematol Educ Program. 2015;2015(1):82\u201391.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"21","key":"131_CR13","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1182\/blood.V120.21.1643.1643","volume":"120","author":"KA Blum","year":"2012","unstructured":"Blum KA, Christian B, Flynn JM, Jaglowski SM, Jones JA, Maddocks K, et al. A phase I trial of the Bruton\u2019s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) in combination with rituximab (R) and bendamustine in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma (NHL). Blood. 2012;120(21):1643.","journal-title":"Blood"},{"issue":"2","key":"131_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1182\/bloodadvances.2018026401","volume":"3","author":"DJ Landsburg","year":"2019","unstructured":"Landsburg DJ, Hughes ME, Koike A, Bond D, Maddocks KJ, Guo L, et al. Outcomes of patients with relapsed\/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy. Blood Adv. 2019;3(2):132\u20135.","journal-title":"Blood Adv"},{"issue":"6","key":"131_CR15","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","volume":"21","author":"Y-B Chen","year":"2015","unstructured":"Chen Y-B, Lane AA, Logan BR, Zhu X, Akpek G, Aljurf M, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):1046\u201353.","journal-title":"Biol Blood Marrow Transplant"},{"key":"131_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.leukres.2019.01.002","volume":"79","author":"C Lemieux","year":"2019","unstructured":"Lemieux C, Ahmad I, Bambace NM, Bernard L, Cohen S, Delisle JS, et al. Outcome of autologous hematopoietic stem cell transplant in older patients with B-cell lymphoma when selected for fitness and chemosensitive disease. Leuk Res. 2019;79:75\u201380.","journal-title":"Leuk Res"},{"issue":"1","key":"131_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bbmt.2007.06.016","volume":"14","author":"JM Vose","year":"2008","unstructured":"Vose JM, Bierman PJ, Loberiza FR, Lynch JC, Bociek GR, Weisenburger DD, et al. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: Effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant. 2008;14(1):36\u201342.","journal-title":"Biol Blood Marrow Transplant"},{"key":"131_CR18","unstructured":"Bashir Q, Hamadani M. Hematopoietic cell transplantation for malignant conditions. St. Louis, Missouri: Elsevier Health Sciences; 2019."},{"issue":"5","key":"131_CR19","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/sj.leu.2401417","volume":"13","author":"C Dumontet","year":"1999","unstructured":"Dumontet C, Drai J, Bienvenu J, Berard EN, Thieblemont C, Bouafia F, et al. Profiles and prognostic values of LDH isoenzymes in patients with non-Hodgkin\u2019s lymphoma. Leukemia. 1999;13(5):811\u20137.","journal-title":"Leukemia"},{"issue":"1","key":"131_CR20","volume":"4","author":"BD Cheson","year":"2015","unstructured":"Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol. 2015;4(1):5.","journal-title":"Chin Clin Oncol"},{"issue":"1","key":"131_CR21","first-page":"46","volume":"50","author":"S Mathur","year":"2007","unstructured":"Mathur S, Dawar R, Verma K. Diagnosis and grading of non-Hodgkin\u2019s lymphomas on fine-needle aspiration cytology. Indian J Pathol Microbiol. 2007;50(1):46\u201350.","journal-title":"Indian J Pathol Microbiol"},{"key":"131_CR22","doi-asserted-by":"publisher","first-page":"584","DOI":"10.12659\/AOT.918259","volume":"24","author":"AL Ron-Maga\u00f1a","year":"2019","unstructured":"Ron-Maga\u00f1a AL, Fernandez-Vargas OE, Barrera-Chairez E, Ron-Guerrero CS, Ba\u00f1uelos-\u00c1vila AJ. BEAM-modified conditioning therapy with cisplatin + dexamethasone instead of carmustine prior to autologous hematopoietic stem cell transplantation (HSCT) in patients with Hodgkin and non-Hodgkin lymphoma. Ann Transplant. 2019;24:584\u20137.","journal-title":"Ann Transplant"},{"key":"131_CR23","volume":"2021","author":"EA Pangarsa","year":"2021","unstructured":"Pangarsa EA, Naibaho RM, Yunarvika V, Setiawan B, Santosa D, Suharti C. The use of etoposide, Ara-cytarabine, and melphalan (EAM) conditioning chemotherapy in autologous stem cell transplantation (ASCT) for a patient with relapsed Hodgkin\u2019s lymphoma. Case Rep Hematol. 2021;2021:9632427.","journal-title":"Case Rep Hematol"},{"issue":"11","key":"131_CR24","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/bmt.2013.90","volume":"48","author":"J Loke","year":"2013","unstructured":"Loke J, Ward J, Mahendra P, Chaganti S, Malladi R. Outcomes of EAM-conditioned autologous haematopoietic SCT for lymphoma: a matched-pairs retrospective single-centre study analysis. Bone Marrow Transplant. 2013;48(11):1486\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"131_CR25","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s41409-018-0243-0","volume":"53","author":"MA Bekadja","year":"2018","unstructured":"Bekadja MA, Talhi S, Amani K, Osmani S, Brahimi M, Mazari MA, et al. Outcomes of modified-EAM-conditioned autologous non-cryopreserved hematopoietic SCT for lymphoma: A retrospective single-centre study. Bone Marrow Transplant. 2018;53(12):1596\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"131_CR26","unstructured":"Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual. 8th ed. New York: Springer; 2017."},{"issue":"1","key":"131_CR27","first-page":"43","volume":"15","author":"G Caponetti","year":"2017","unstructured":"Caponetti G, Bagg A. Demystifying the diagnosis and classification of lymphoma: a hematologist\/oncologist\u2019s guide to the hematopathologist\u2019s galaxy. J Community Support Oncol. 2017;15(1):43\u20138.","journal-title":"J Community Support Oncol"},{"issue":"5","key":"131_CR28","first-page":"489","volume":"30","author":"A Miranda-Filho","year":"2019","unstructured":"Miranda-Filho A, Pi\u00f1eros M, Znaor A, Marcos-Gragera R, Steliarova-Foucher E, Bray F. Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control. 2019;30(5):489\u201399.","journal-title":"Cancer Causes Control"},{"issue":"23","key":"131_CR29","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1995;333(23):1540\u20135.","journal-title":"N Engl J Med"},{"issue":"7","key":"131_CR30","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/bmt.2016.340","volume":"52","author":"G Damaj","year":"2017","unstructured":"Damaj G, Cornillon J, Bouabdallah K, Gressin R, Vigouroux S, Gastinne T, et al. Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: A review. Bone Marrow Transplant. 2017;52(7):941\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"131_CR31","doi-asserted-by":"crossref","unstructured":"Jo JC, Kang BW, Jang Get, Sym SJ, Lee SS, Koo JE, et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin\u2019s lymphoma patients: Comparative analysis of efficacy and toxicity. Ann Hematol. 2008;87(1):43\u201348.","DOI":"10.1007\/s00277-007-0360-0"},{"issue":"7","key":"131_CR32","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1080\/1042819031000083028","volume":"44","author":"E Jantunen","year":"2003","unstructured":"Jantunen E, Kuittinen T, Nousiainen T. BEAC or BEAM for high-dose therapy in patients with non-Hodgkin\u2019s lymphoma? A single-centre analysis on toxicity and efficacy. Leuk Lymphoma. 2003;44(7):1151\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"131_CR33","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/sj.bmt.1700913","volume":"20","author":"MD Caballero","year":"1997","unstructured":"Caballero MD, Rubio V, Rifon J, Heras I, Garc\u00eda-Sanz R, V\u00e1zquez L, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant. 1997;20(6):451\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"131_CR34","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.3109\/10428194.2015.1028054","volume":"56","author":"I Sakellari","year":"2015","unstructured":"Sakellari I, Mallouri D, Batsis I, Apostolou C, Konstantinou V, Abela EM, et al. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: A retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas. Leuk Lymphoma. 2015;56(11):3071\u201381.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"131_CR35","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.bbmt.2019.01.032","volume":"25","author":"S Singer","year":"2019","unstructured":"Singer S, Sharma N, Dean R, Zhao Q, Abounader D, Elder P, et al. BEAM or BUCYVP16 conditioning regimen for autologous stem-cell transplantation in non-Hodgkin\u2019s lymphomas. Bone Marrow Transplant. 2019;25(6):1107\u201315.","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 1","key":"131_CR36","doi-asserted-by":"publisher","first-page":"S306","DOI":"10.1016\/j.clml.2018.07.266","volume":"18","author":"GC Seval","year":"2018","unstructured":"Seval GC, Sahin DG, Soydan EA, Ozcelik T, Gokmen A, Gokgoz Z, et al. Comparing conditioning remigens for autologous stem cell transplantation in lymphoma patients. Clin Lymphoma Myeloma Leuk. 2018;18(Suppl 1):S306.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"131_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/hon.956","volume":"29","author":"J Pavlu","year":"2011","unstructured":"Pavlu J, Auner HW, Ellis S, Szydlo RM, Giles C, Contento A, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: Treatment outcome and risk factor analysis from a single centre. Hematol Oncol. 2011;29:75\u201380.","journal-title":"Hematol Oncol"},{"key":"131_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/sj.bmt.1705544","volume":"39","author":"JB Perz","year":"2007","unstructured":"Perz JB, Giles C, Szydlo R, O\u2019She D, Sanz J, Chaidos A, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin\u2019s lymphoma: Treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant. 2007;39:41\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"131_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.exphem.2013.09.012","volume":"42","author":"NM Reddy","year":"2014","unstructured":"Reddy NM, Oluwole O, Greer JP, Engelhardt BG, Jagasia MH, Savani BN. Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma. Exp Hematol. 2014;42(1):39\u201345.","journal-title":"Exp Hematol"},{"key":"131_CR40","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1200\/JCO.1994.12.12.2559","volume":"12","author":"CH Weaver","year":"1994","unstructured":"Weaver CH, Petersen FB, Appelbaum FR, Bensinger WI, Press O, Martin P, et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem cell support in patients with malignant lymphoma. J Clin Oncol. 1994;12:2559\u201366.","journal-title":"J Clin Oncol"},{"key":"131_CR41","first-page":"261","volume":"3","author":"K Schiffman","year":"1997","unstructured":"Schiffman K, Buckner CD, Maziarz R, Maloney DG, Appelbaum FR, Press O, et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin\u2019s disease. Biol Blood Marrow Transplant. 1997;3:261\u20136.","journal-title":"Biol Blood Marrow Transplant"},{"key":"131_CR42","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1200\/JCO.1990.8.4.648","volume":"8","author":"C Wheeler","year":"1990","unstructured":"Wheeler C, Antin JH, Churchill M, Come SE, Smith BR, Bubley GJ, et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma: A dose-finding study. J Clin Oncol. 1990;8:648\u201354.","journal-title":"J Clin Oncol"},{"key":"131_CR43","first-page":"382","volume":"12","author":"SJ Horning","year":"1993","unstructured":"Horning SJ, Negrin RS, Chao NJ, Couture F, Sherret H, Sutton DM, et al. High-dose etoposide regimens and autologous bone marrow transplantation (ABMT) for malignant lymphoma: Results in 202 consecutive patients. Proc ASCO. 1993;12:382.","journal-title":"Proc ASCO"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00131-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00131-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00131-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:42:39Z","timestamp":1776069759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00131-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["131"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00131-8","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the Ethics Committee of Tehran University of Medical Sciences. The procedures used in this study adhered to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}